Juvederm Vollure XC (Allergan) has been approved for injection into facial tissue, in adults 21 years of age and older, for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.
The approval is based on results from a US pivotal clinical trial in which 59% of patients saw improvement in moderate to severe nasolabial folds for up to 18 months. According to the results, 82% of patients reported that they were very satisfied at 6 months, and 68% reported high satisfaction at 18 months.
The most commonly reported side effects during the clinical trial included temporary site injection site responses such as swelling, tenderness, bruising, firmness lumps and bumps, redness, pain, discoloration, and itching. Most patients who experienced side effects said it was resolved within 1 week.
Juvederm Vollure XC was first approved as Juvederm Volift in 2013 in Europe. The product uses Vycross technology, which is designed to blend different molecular weights of hyaluronic acid.
Juvederm Vollure XC is expected to be available in April 2017.
Juvederm Vollure XC (Allergan) has been approved for injection into facial tissue, in adults 21 years of age and older, for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.
The approval is based on results from a US pivotal clinical trial in which 59% of patients saw improvement in moderate to severe nasolabial folds for up to 18 months. According to the results, 82% of patients reported that they were very satisfied at 6 months, and 68% reported high satisfaction at 18 months.
The most commonly reported side effects during the clinical trial included temporary site injection site responses such as swelling, tenderness, bruising, firmness lumps and bumps, redness, pain, discoloration, and itching. Most patients who experienced side effects said it was resolved within 1 week.
Juvederm Vollure XC was first approved as Juvederm Volift in 2013 in Europe. The product uses Vycross technology, which is designed to blend different molecular weights of hyaluronic acid.
Juvederm Vollure XC is expected to be available in April 2017.
Juvederm Vollure XC (Allergan) has been approved for injection into facial tissue, in adults 21 years of age and older, for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.
The approval is based on results from a US pivotal clinical trial in which 59% of patients saw improvement in moderate to severe nasolabial folds for up to 18 months. According to the results, 82% of patients reported that they were very satisfied at 6 months, and 68% reported high satisfaction at 18 months.
The most commonly reported side effects during the clinical trial included temporary site injection site responses such as swelling, tenderness, bruising, firmness lumps and bumps, redness, pain, discoloration, and itching. Most patients who experienced side effects said it was resolved within 1 week.
Juvederm Vollure XC was first approved as Juvederm Volift in 2013 in Europe. The product uses Vycross technology, which is designed to blend different molecular weights of hyaluronic acid.
Juvederm Vollure XC is expected to be available in April 2017.
